Venus Remedies Limited (VENUSREM)
₹1,650.70 +4.99% last close, 16 Oct
Q2 FY27 results
📅 Next results: 26 Oct 2026 (board meeting)Venus Remedies Limited's board meets on 26 Oct 2026 to consider its Q2 FY27 results (July-September 2026).
In its latest reported quarter, Q1 FY27, Venus Remedies' revenue was ₹179 Cr (+35.6% year on year, -30.9% on the previous quarter), and net profit ₹23.0 Cr (+139.3% year on year); the operating margin was 19.1%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹179 | +35.6% | -30.9% |
| Operating profit | ₹34.2 | +238.5% | -45.7% |
| Net profit | ₹23.0 | +139.3% | -52.1% |
| EPS (₹) | 17.18 | +139.3% | -51.7% |
| Operating margin | 19.1% | — | — |
VENUSREM exchange data
NSE end-of-day data for
It closed at its upper price band (circuit) on 16 Oct, one of 5 band closes in about the last 20 sessions.
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Venus Remedies has secured five marketing authorisations across Kazakhstan, Peru, Kuwait, and Argentina. The approved products include critical-care and oncology injectables: Vancomycin and Fluorouracil in Kazakhstan, Fulvestrant in Peru, Methotrexate in Kuwait, and Meropenem in Argentina. These approvals expand the company's existing footprint of over 100 countries across the CIS, Latin America, and Middle East regions. Commercial revenue potential and launch timelines were not disclosed.
- Secured 5 marketing authorisations across 4 international markets
- Approvals span Kazakhstan (Vancomycin, Fluorouracil), Peru (Fulvestrant), Kuwait (Methotrexate), and Argentina (Meropenem)
- Geographic scope covers CIS, Latin America, and Middle East regions
- Adds to company's global footprint spanning over 100 countries
Venus Remedies Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate was issued by its Registrar & Transfer Agent, MUFG Intime India Pvt Ltd, on October 7, 2026. It confirms that securities received for dematerialisation during the period were processed, confirmed or rejected, and mutilated/cancelled within prescribed timelines. This is a standard administrative compliance filing with no impact on business operations or financials.
- Compliance submitted under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
- Covers the quarter ended on 30th September 2026
- Certificate issued by RTA MUFG Intime India Pvt Ltd on October 7, 2026
- Filing dated October 9, 2026
Venus Remedies Limited has submitted an intimation regarding social media posts published across its platforms (Facebook, Instagram, LinkedIn, and X). The posts inform shareholders about the opening of a special window for the re-lodgement of transfer requests for physical shares. This action is undertaken in compliance with SEBI circulars dated July 02, 2025, and January 30, 2026. The announcement is strictly procedural investor awareness and carries no financial impact on the company.
- Published investor awareness posts across official social media handles (Facebook, Instagram, LinkedIn, X)
- Notified shareholders regarding the special window for re-lodgement of physical share transfer requests
- Issued in compliance with SEBI circulars dated July 02, 2025 and January 30, 2026
Venus Remedies Limited has refiled its shareholder meeting voting results along with the Scrutinizer's report on August 21, 2026. The re-submission was made because the previously submitted document was not machine readable. This is a routine compliance filing with no impact on the company's operational or financial metrics.
- Resubmission of shareholder meeting voting results and Scrutinizer report
- Filing rectified as the earlier submission was not machine readable
- Signed and submitted on August 21, 2026
- Procedural compliance update with no material change to business fundamentals
Venus Remedies Limited has submitted the Scrutinizer's report and voting results for its Annual General Meeting held on August 20, 2026. This is a standard statutory compliance filing following the conclusion of the AGM. Detailed resolution-by-resolution vote counts were submitted to the exchange pursuant to SEBI regulations. There are no operational or financial surprises arising from this administrative disclosure.
- Annual General Meeting conducted on August 20, 2026
- Scrutinizer's report and voting results submitted to exchanges on August 21, 2026
- Statutory disclosure under SEBI (LODR) Regulations
Venus Remedies Limited announced that its shareholders approved the alteration of its Memorandum of Association (MOA) and Articles of Association (AOA) at the Annual General Meeting on August 20, 2026. The updates replace legacy provisions under the Companies Act, 1956, aligning the company's charter with Table-A and Table-F of the Companies Act, 2013. The Object Clause has been updated to comprehensively cover pharmaceutical, CDMO/CRO, biologics, and digital healthcare activities, while core business operations remain unchanged.
- Shareholders approved MOA and AOA alterations at the AGM held on August 20, 2026.
- Adopted new AOA based on Table-F of Schedule I of the Companies Act, 2013, replacing 1956 Act references.
- Object Clause updated to formally cover CDMO, CRO, digital health platforms, and allied services without altering core operations.
Venus Remedies placed the appointments and re-appointments of key board members before shareholders at its 37th Annual General Meeting on August 20, 2026. Mr. Saransh Chaudhary was appointed as Executive Director (Whole-time Director) for 5 years effective May 26, 2026. The AGM also considered the appointment of Dr. Gurminder Singh Bedi as Independent Director for 5 years, along with 5-year re-appointments for Joint Managing Director Dr. Manu Chaudhary (effective October 1, 2026) and Independent Director Dr. Savita Gupta (effective December 30, 2026). Voting results and the scrutinizer report will follow within statutory timelines.
- Appointment of Mr. Saransh Chaudhary as Executive Director for a 5-year term effective May 26, 2026
- Re-appointment of Dr. (Mrs.) Manu Chaudhary as Joint Managing Director for 5 years starting October 1, 2026 (holds 15,68,000 shares)
- Appointment of Dr. Gurminder Singh Bedi as Non-Executive Independent Director for 5 years effective May 26, 2026
- Re-appointment of Dr. (Mrs.) Savita Gupta as Independent Director for a 2nd 5-year term from December 30, 2026
Venus Remedies Limited conducted its 37th Annual General Meeting (AGM) on August 20, 2026, with 59 members in attendance. Key resolutions tabled for shareholder voting included the declaration of a final dividend of Rs 10 per equity share (100% on face value of Rs 10), adoption of FY26 financial statements, and alteration of the Memorandum and Articles of Association. Additionally, resolutions covered the appointment and re-appointment of executive and independent directors, including the re-appointment of Dr. Manu Chaudhary as Joint Managing Director for a 5-year term. Final e-voting and scrutinizer results will be submitted within 48 hours.
- Tabled declaration of final dividend of Rs 10 per equity share (100% on face value of Rs 10)
- Approved resolutions for re-appointment of Dr. (Mrs.) Manu Chaudhary as Joint Managing Director and appointment of Mr. Saransh Chaudhary as Executive Director for 5 years
- Cost auditor remuneration ratified at Rs 1,10,000 per annum for FY 2026-27
- Total 59 members attended the virtual AGM, with voting results to be declared within 48 hours
Venus Remedies has scheduled its 37th Annual General Meeting (AGM) for August 20, 2026, to approve a final dividend of ₹10 per share (100% of face value). The record date for dividend eligibility is August 7, 2026. The company is also seeking shareholder approval for the appointment of Mr. Saransh Chaudhary as Executive Director for a five-year term at an annual salary of ₹93 Lacs. This follows a strong financial year where TTM PAT reached ₹103 Cr, a significant increase from ₹45.33 Cr in FY25.
- Final dividend of ₹10 per equity share (100% of face value) recommended for FY 2025-26.
- Record date for dividend eligibility set for August 7, 2026, with the AGM on August 20, 2026.
- Appointment of Mr. Saransh Chaudhary as Executive Director for 5 years at a salary of ₹93.00 Lacs per annum.
- Proposed annual increment for the new Executive Director capped at 20% starting January 1st each year.
- Ratification of Cost Auditor remuneration at ₹1,10,000 for the financial year 2026-27.
Venus Remedies reported a strong start to FY27 with standalone revenue growing 30.4% YoY to ₹178.80 cr. Net profit surged 118.2% YoY to ₹25.53 cr, with EPS rising to ₹19.40 from ₹8.75 in the year-ago quarter. The board also approved revisions to the Memorandum of Association (MOA) to align with the Companies Act 2013 and accommodate 'proposed business activities'. However, auditors highlighted ₹28.59 cr in pending share allotments for the German subsidiary, which is currently facing financial challenges and undergoing restructuring.
- Standalone Revenue from Operations grew 30.4% YoY to ₹178.80 cr in Q1 FY27.
- Net Profit increased by 118.2% YoY to ₹25.53 cr, up from ₹11.70 cr in Q1 FY26.
- EBITDA for the quarter stood at ₹39.11 cr, representing a margin of 21.9% compared to 15.1% in the previous year.
- Outstanding share application money of ₹28.59 cr in German subsidiary Venus Pharma GmbH remains pending allotment.
- Research & Development expenses for the quarter were ₹4.23 cr, approximately 2.4% of revenue.
Venus Remedies reported a strong start to FY27 with standalone revenue growing 30.4% YoY to ₹178.80 Cr. Net profit surged 118.2% YoY to ₹25.53 Cr, driven by significant operational leverage as EBITDA margins expanded from 15.1% to 21.9%. The board also approved updating the Memorandum of Association to include CDMO and CRO activities, signaling a strategic shift. However, auditors highlighted financial challenges at the German subsidiary, where ₹28.60 Cr in share application money remains pending allotment.
- Standalone Revenue from Operations increased 30.4% YoY to ₹178.80 Cr from ₹137.13 Cr.
- Net Profit grew by 118.2% YoY to ₹25.53 Cr compared to ₹11.70 Cr in the same quarter last year.
- EBITDA rose 89.3% YoY to ₹39.11 Cr, reflecting improved manufacturing and administrative efficiencies.
- R&D expenses for the quarter stood at ₹4.23 Cr, approximately 2.3% of total income.
- Auditor flagged ₹28.60 Cr (approx.) in outstanding share application money for the German subsidiary which is facing financial challenges.
Venus Remedies has notified the exchange regarding a social media campaign aimed at encouraging shareholders to update their KYC details. The outreach is being conducted across four major platforms: Instagram, Facebook, LinkedIn, and X. This is a standard administrative procedure to ensure compliance with regulatory requirements for shareholder records. It has no impact on the company's financial performance or market valuation of Rs 2377 Cr.
- Outreach conducted across 4 social media platforms including X and LinkedIn
- Filing submitted on July 18, 2026, under SEBI Regulation 30
- Company reported TTM Revenue of Rs 764 Cr as of the latest financial context
Venus Remedies Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by MUFG Link Intime India Pvt Ltd, confirms that share certificates received for dematerialization during the quarter ended June 30, 2026, have been processed. This is a standard administrative filing required for all listed entities to confirm the reconciliation of share records with depositories. It has no impact on the company's financial health or its TTM revenue of ₹764 Cr.
- Compliance certificate issued for the quarter ended June 30, 2026
- Confirmation received from Registrar & Transfer Agent, MUFG Link Intime India Pvt Ltd
- Filing submitted to exchanges on July 10, 2026
- Confirms adherence to SEBI (Depositories and Participants) Regulations, 2018
Venus Remedies has announced the opening of a special window for shareholders to re-lodge transfer requests for physical shares. This move follows SEBI circulars dated July 02, 2025, and January 30, 2026, aimed at streamlining legacy physical holdings. The company is utilizing social media platforms including X, LinkedIn, Facebook, and Instagram to increase awareness among its shareholder base. This is a procedural regulatory update and does not impact the company's financial operations or market valuation of Rs 2243 Cr.
- Special window opened for re-lodgement of physical share transfer requests per SEBI guidelines.
- Compliance with two specific SEBI circulars dated July 02, 2025, and January 30, 2026.
- Awareness campaign launched across 4 major social media handles (Instagram, Facebook, LinkedIn, and X).
- Procedural update for a company with a TTM revenue of Rs 764 Cr and net worth of Rs 689 Cr.
Venus Remedies Limited has announced the closure of its trading window for all designated persons starting July 1, 2026. This move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as the company prepares to finalize its unaudited financial results for the quarter ending June 30, 2026. The window will remain closed until 48 hours after the financial results are officially declared to the stock exchanges. This is a standard regulatory procedure and does not indicate any fundamental change in the company's operations.
- Trading window closure begins on July 1, 2026
- Closure is related to the financial results for the period ending June 30, 2026
- Window will reopen 48 hours after the declaration of unaudited financial results
- Applicable to all Designated Persons under SEBI Insider Trading regulations
Financial Performance
Revenue Growth by Segment
Consolidated revenue grew 7.72% YoY to ₹647.89 Cr in FY25, while standalone revenue grew 11.17% to ₹639.46 Cr. Growth was driven by critical care, anti-infectives, and oncology divisions.
Geographic Revenue Split
Not disclosed in specific percentages, but the company reported strong export momentum and expanded marketing efforts in key global markets including Europe, ASEAN, and Africa.
Profitability Margins
Net Profit Margin improved from 5.20% in FY24 to 7.96% in FY25. Consolidated Profit After Tax (PAT) grew 59.05% YoY to ₹45.31 Cr, while standalone PAT grew 72.34% to ₹52.56 Cr.
EBITDA Margin
EBITDA increased 18.7% YoY from ₹71.18 Cr in FY24 to ₹84.49 Cr in FY25, representing an EBITDA margin of approximately 13.04%.
Capital Expenditure
Not disclosed in absolute INR Cr for future periods, but the company is prioritizing 'sustainability-first construction' for all future sites and investing in digital infrastructure.
Credit Rating & Borrowing
The company was rated 'CRISIL D (ISSUER NOT COOPERATING)' as of October 2020. Interest costs are maintained low, at less than 1% of total revenues.
Operational Drivers
Raw Materials
Specific names not disclosed; categorized as 'imported raw materials' and components for pharmaceutical formulations.
Key Suppliers
Not disclosed in available documents; company uses multiple supplier contracts to mitigate disruption risks.
Capacity Expansion
Current capacity not disclosed in units; expansion plans focus on the Global Venus Fulfilment Centre (Global VFC) and automation of critical processes.
Raw Material Costs
Cost of material consumed remained largely at the previous year's level despite a 7.72% increase in consolidated revenue, indicating improved procurement efficiency.
Manufacturing Efficiency
Internal rejection rates were eliminated (0 rejections) in FY25, down from 1 in FY24 and 2 in FY23, through strengthened in-process controls.
Strategic Growth
Expected Growth Rate
7.72%
Growth Strategy
Growth will be achieved through the commercialization of intellectual property assets, completion of AMR licensing milestones (final €1.1 Cr payment), and expansion of digital literature with QR codes in domestic markets.
Products & Services
Pharmaceutical formulations in critical care, anti-infectives, oncology, and research-based products like VRP-034.
Brand Portfolio
Venus Remedies, Venus Pharma GmbH, Venus Care.
New Products/Services
VRP-034 received USFDA QIDP designation; company is focusing on marketing authorisations for IP-led formulations.
Market Expansion
Targeting further growth in European markets and domestic expansion through digital branding and social media strategies.
Strategic Alliances
AMR Licensing agreement (milestone completed with €1.1 Cr payment); collaboration with government Skill Sector councils for digital assessments.
External Factors
Industry Trends
The industry is shifting toward digital literature, automated quality management, and stricter compliance with EU GMP Annexe I and Schedule M updates.
Competitive Landscape
Competitive edge maintained through R&D-led formulations versus pure generic drug production.
Competitive Moat
Durable moat through 130+ secured patents, 25+ GMP certifications (including EU-GMP), and USFDA QIDP designation for research products.
Macro Economic Sensitivity
Sensitive to global demand fluctuations and economic uncertainties affecting pharmaceutical exports.
Consumer Behavior
Increasing demand for transparent product data, addressed by the company through digital literature and QR codes.
Geopolitical Risks
Global supply chain disruptions for raw materials and stringent global standards for injectables.
Regulatory & Governance
Industry Regulations
Compliance with EU GMP Annexe I (ORABS and Automatic Lyoloading) and Schedule M updates for sterile disinfectants.
Environmental Compliance
Investing in 'sustainability-first construction', Scope 3 emissions frameworks, and carbon-neutral roadmaps.
Taxation Policy Impact
Resolved all pending Income Tax matters; contingent liability of ₹33.44 Cr reduced to nil with refunds received.
Legal Contingencies
Previously reported contingent liability of ₹33.44 Cr related to Income Tax is now nil following favorable appellate decisions.
Risk Analysis
Key Uncertainties
Regulatory setbacks or negative publicity could impact global brand trust; IP disputes could undermine R&D efforts.
Geographic Concentration Risk
Not disclosed, but company has a presence in 51 countries across Europe, North America, and ASEAN.
Third Party Dependencies
Reliance on imported raw materials is a key dependency; mitigated by multiple supplier contracts.
Technology Obsolescence Risk
Mitigated by digital transformation initiatives including 21 CFR-compliant software and automated payment systems.
Credit & Counterparty Risk
Receivables quality improved through superior working capital management, resulting in ₹86.44 Cr operating cash flow.
